ADVFN - Advanced Financial Network.
HOME» AMEX » P » PTN Stock Price » PTN Stock News

Palatin Share News

 Palatin Technologies, Stock Price
PTN Stock Price
 Palatin Technologies, Stock Chart
PTN Stock Chart
 Palatin Technologies, Stock News
PTN Stock News
 Palatin Technologies, Company Information
PTN Company Information
 Palatin Technologies, Stock Trades
PTN Stock Trades

Palatin Tech 4Q Loss Widens Sharply As Revenue Plunges

DOW JONES NEWSWIRES Palatin Technologies Inc. (PTN), the biopharmaceutical company that announced major retrenching Friday, said its fiscal fourth-quarter loss widened sharply as revenue plunged. Palatin attributed the wider loss to lower payments from AstraZeneca PLC (AZN) for research services. Such fees had dropped in the prior quarter but had increased in earlier periods. On Friday, Palatin announced it would halve its 40-person work force and narrow its research focus. It also said it would implement a one-for-10 reverse stock split, which was required for the company to keep its listing on the NYSE Amex exchange. Palatin has been developing treatments for male and female sexual dysfunction and acute severe asthma. For the period ended June 30, Palatin posted a loss of $4.2 million, or 40 cents a share, compared with a year-earlier loss of $200,530, or 2 cents a share. Revenue plunged 84% to $674,957. Results were reported on a "post-reverse-split basis." There were 10.7 million shares outstanding at the end of the period. Cash levels were at $8.9 million as of June 30, up from $7.9 million a year earlier. Patalin said Friday its restructuring will cut operating costs some $5.6 million a year; they totaled $17.2 million in the latest fiscal year. Shares closed Friday at $1.80 and were inactive premarket. The stock is down 51% this year after tripling in 2009. -By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com

Stock News for Palatin (PTN)
DateTimeHeadline
09/07/201208:41:51Palatin Tech Says AstraZeneca Halts Further Development of Obesity...
06/19/201208:34:05Palatin, AstraZeneca Obesity Drug Trial Halted on Adverse Event
09/27/201008:29:05Palatin Tech 4Q Loss Widens Sharply As Revenue Plunges

Palatin Tech and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad